Docaravimab-Miromavimab
| Product Overview | |
| Generic Name | Docaravimab-Miromavimab |
| Brand Name(s) | TwinRab™ |
| Form | 2.5 mL Vial (300 iu docaravimab / 300 iu miromavimab) |
| Strength | 1500 IU / 2.5 mL |
| Therapeutic Class | Rabies post-exposure prophylaxis biologic (administered with rabies vaccine) |
| ATC Code | J06BB05 |
| Manufacturing & Regulatory | |
| Manufacturer | Zydus |
| Country | Inda |
| GMP Compliance | WHO-GMP certificate |
| DMF/CEP | Not publicly available |
| COFEPRIS | Not verifiable |
| Free Sale Certificate | Potentially available if exported via authorized channel |
| Logistics & Export | |
| MOQ | RFQ-Dependent, 100pcs |
| Shelf Life | 24 Months |
| Storage | 2–8 °C; do not freeze; do not shake; protect from light. |
| Incoterms | RFQ-dependent... |
| Lead Time | RFQ-dependent |
| Documentation | |
| Certificate of Analysis (COA) | Yes (typical) via manufacturer/authorized distributor as batch/lot CoA |
| SDS | available as GHS/CLP-style SDS |
| CTD Summary | Not publicly posted as CTD; however, a product information leaflet (PI) exists |
Description
an anti-rabies monoclonal antibody combination used for rabies post-exposure prophylaxis. TwinRab product information identifies it as an equipotent mixture of docaravimab and miromavimab binding to distinct sites on rabies virus.
